Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Recurrence 1Pain 1Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Melanoma 1Gallbladder Neoplasms 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × AZD 6244 × Clear all
NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
90 enrolled
Breast

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

UNICANCER

Phase 2 Active not recruiting
1,460 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡